New Insight with Dr. Veeral Sheth

Relatable Rheumatology: From Stories to Studies

Diabetes Dialogue

Don’t Miss a Beat

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Laundry detergents—specifically their sodium dodecyl sulfate (SDS) component—impact the epidermal barrier of both living human skin and ex vivo skin, according to recent findings, and consistent exposure to detergents could disrupt the skin's protective barrier and affect the emergence of 

These findings were observed in a new study conducted following a rising tide of research showing an epidemiological link between domestic and professional cleaning agents such as detergents, with studies often highlighting increases in prevalence of rhinitis, asthma, and allergic contact dermatitis.

Led by Arturo O. Rinaldi from the Swiss Institute of Allergy and Asthma

Research reveals that sodium dodecyl sulfate (SDS) in laundry detergents can potentially contributing to the development of atopic conditions.

Conducted on mice and ex vivo human skin, demonstrates exposure to common household laundry detergents reduces skin barrier integrity, with a marked decrease in electric impedance and increased transepidermal water loss.

Indicated that changes in gene expression and protein levels related to skin barrier function.

Highlighted the need for further investigation into the long-term effects of detergents on the skin, especially in those with skin disturbances.

This new research into the components of detergent and their effects on the skin’s barrier was led by Arturo O. Rinaldi, from the Swiss Institute of Allergy and Asthma Research (SIAF) at University of Zürich in Davos, Switzerland.

“The present study aims to evaluate the in vivo effects of household laundry detergents on skin barrier integrity, even used at low concentration,” Rinaldi and colleagues wrote. “We treated mouse skin with different dilutions of two household laundry detergents…”

The study’s investigators bought C57BL/6 mice from Charles River in Germany, keeping them in a specific-pathogen-free area within the AO Research Institute in Davos. The team utilized these mice for experiments when they were 8 - 12 weeks of age.

After removing the hair from their back skin with an epilation cream, the investigators gave the mice an incubation period of 3 days and, subsequently, the mice were subjected to the application of 2 common household laundry detergents, denoted as detergents A and B.

These 2 detergents were applied by the research team with a skin patch and were administered at varying dilutions (1:100, 1:1000, and 1:10,000 with phosphate-buffered saline [PBS]) for a total duration of 4 hours. In the initial experiments, the team assessed various time intervals, ultimately deciding that the most suitable time frame for the investigation was 4 hours.

As a control and for the purpose of dilution, PBS was used in the investigators’ research. After the specified time intervals, the mice in the experiment were humanely euthanized, and samples of the treated skin were meticulously gathered. Ex vivo human skin samples were acquired by the team through purchase.

Human skin samples were obtained from individuals who had undergone abdominoplasty procedures and had provided written informed consent, and the investigators noted that the donors had no history of dermatological conditions, allergies, or corticosteroids.

The adult skin explants used by the research team originated from 2 female donors—aged 32, 37, and 57 years—all of whom were shown to be in good health. Each sample consisted of naturally obtained 15mm diameter circular skin biopsies, and these were encased by the team in custom-built plastic inserts.

Following their 4-hour exposure process with the detergents, the investigators evaluated the skin's barrier function through electric impedance spectroscopy (EIS) and measurements of transepidermal water loss (TEWL). The research team’s skin biopsy samples were given both RNA sequencing (RNA-seq) and targeted multiplex proteomics analyses. Furthermore, they noted that the impact of a 6-hour treatment with detergent and SDS on ex vivo human skin was examined.

The team noted in their conclusions that the detergent exposure led to a distinct reduction in EIS as well as an increase in TEWL versus untreated skin. In fact, EIS was shown to have a more heightened sensitivity to the treatment and it indicated a clear dose-response relationship.

The investigators’ RNA-seq analysis’s results indicated a reduction in the expression of several different genes known to be necessary for the skin's barrier integrity, including ones known to be responsible for tight junctions and adherens junction proteins. In contrast, the team reported an upregulation in the genes linked to lipid metabolic processes, keratinization, and differentiation of epidermal cells.

The research team’s proteomics analysis led to the conclusion that there was a general downregulation of proteins linked to cell adhesion, such as epithelial cell adhesion molecule and contactin-1. Meanwhile, proinflammatory proteins such as interleukin-1 beta and interleukin-6 were upregulated.

The investigators noted the importance of acknowledging that both SDS and detergents resulted in a major decrease in EIS values in the ex vivo human skin model.

“Overall, our data indicate that laundry detergents can impact the epidermis integrity and suggest further research to evaluate the long-term effect of detergents on the skin barrier, particularly in patients with skin disturbances,” they wrote.

Rinaldi, AO, Li, M, Barletta, E, et al. Household laundry detergents disrupt barrier integrity and induce inflammation in mouse and human skin. Allergy. 2023; 00: 1-13. doi:10.1111/all.15891.

Folletti I, Siracusa A, Paolocci G. Update on asthma and cleaning agents. Curr Opin Allergy Clin Immunol. 2017; 17(2): 90-95.

Articles

This new research into detergent’s impact on human skin barrier dysfunction may lead to investigation by public health authorities in the near future due to its implications.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Consistent Exposure to Laundry Detergent Shown to Contribute to Emergence of Atopic Conditions

Connor Iapoce is an associate editor for 

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

The use of sodium-glucose cotransporter-2 (SGLT2) inhibitors was associated with a similar risk of fracture as incretin-based drugs among postmenopausal individuals with 

Analyses showed the risk of fractures was not increased with the use of SGLT2 inhibitors and remained consistent regardless of the incretin-based comparator drug, including dipeptidyl-peptidase 4 inhibitors (DPP4i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA).

“These findings indicate that SGLT2i has either similar or lower risks of fractures than incretin-based drugs even in a population at higher risk for fractures, providing reassurance to and helping health care professionals with their clinical decision-making,” wrote the investigative team, led by Ju-Young Shin, PhD, School of Pharmacy, Sungkyunkwan University.

A heightened risk of fractures in postmenopausal individuals with T2D has been linked to the interaction of elevated blood glucose levels and declining estrogen levels due to menopause. These potential fracture risks are important for clinicians to consider when choosing an optimal pharmacologic regimen for glycemic control in these patients.

 Recent meta-analyses of trials have reported no significant associations between SGLT2i and fracture risk.

However, Shin and colleagues noted, to their knowledge, that no observational studies have assessed the association between their use and fracture risk in postmenopausal individuals with T2D.

 Given this gap in data, Shin and colleagues conducted a nationwide, population-based cohort study to separately compare SGLT2 inhibitors with incretin-based drugs in 2 independent cohorts: SGLT2 inhibitors vs. DPP4i and SGLT2 vs. GLP-1 RA.

The analysis used health administrative claims data from January 2013 - December 2020 obtained from the National Health Insurance Service in South Korea. All female individuals in the database aged 45 years or older were included in the analysis. The index date was the date of the first prescription of either SGLT2 inhibitor or comparator incretin-based drug from September 2014 to December 2020.

Of eligible participants, the investigative team excluded those with severe kidney impairment within the year prior to the index date, to consider for contraindication to SGLT2 inhibitors. Patients were followed up from the index date until the earlier outcome occurrence, drug discontinuation (90-day grace period), switch, death, or end of the study period.

Investigators confirmed the primary outcomes for the analysis were overall fractures, consisting of vertebral, hip, humerus, and distal radius fractures. Secondary outcomes included the invisible components of the primary composite outcome.

A total of 369,570 patients were chosen for the first cohort: 37,532 patients initiating SGLT2 inhibitors (mean age, 60.6 years) and 332,039 patients initiating DPP4 inhibitors (mean age, 66.0 years). For the second cohort, a total of 121,803 patients were selected: 113,622 patients initiating SGLT2 inhibitors (mean age, 61.4 years) and 8181 patients initiating GLP-1 RA (mean age, 62.5 years).

Those in the second cohort showed a higher prevalence of diabetes-related conditions, insulin usage, and more diabetic medication use, suggesting a more severe diabetic profile. Propensity score weighting and trimming left 37,530 patients initiating SGLT2i and 332,004 patients initiating DPP4i in the first cohort, while the second cohort had 111,835 patients initiating SGLT2i and 8177 patients initiating GLP-1 RA.

Upon analysis, in the first cohort, users of SGLT2 inhibitors and DPP4i yielded a weighted incidence of 1.41 and 1.81 events per 100 person-years for the overall fractures, respectively. The data corresponded to a 22% lower rate of incident overall fractures with SGLT2 inhibitors versus DPP4i (weighted hazard ratio [HR], 0.78; 95% CI, 0.72 - 0.84).

Over a mean follow-up of 1.43 years and 0.82 years, the weighted incidence of overall fractures was 1.67 per 100 person-years for SGLT2 inhibitors and 1.92 per 100 person-years for GLP-1 RA. Overall, the analysis showed the use of SGLT2 inhibitors compared with GLP-1 RA was not associated with an increased risk of fractures (weighted HR, 0.92; 95% CI, 0.68 - 1.24).

Similar trends for the secondary outcome were identified across both study cohorts where SGLT2 inhibitors did not increase the risk of fractures, regardless of the comparator drug. Results from subgroup and sensitivity analyses were consistent with the findings in the main analysis.

Shin and colleagues noted that SGLT2 inhibitors potentially disrupt calcium and phosphate homeostasis in serum, which could lead to detrimental effects on bone fragility. Given the decreased levels of estrogen in postmenopausal women, this risk has the potential to be further exacerbated, but more research is required to confirm this mechanism.

“Despite such biological plausibility, our results found a modest potential protective effect of SGLT2 inhibitors against overall fractures, which may be explained by the role of SGLT2i in the trajectory of impaired bone metabolism caused by the accumulation of advanced glycation end products in bone collagen fibers in advanced diabetes,” investigators wrote.

Ko HY, Bea S, Jeong HE, et al. Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes. JAMA Netw Open. 2023;6(9):e2335797. doi:10.1001/jamanetworkopen.2023.35797

Khosla S﻿, Samakkarnthai P﻿, Monroe DG﻿, Farr JN﻿. Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus.

. 2021;17(11):685-697. doi:10.1038/s41574-021-00555-5PubMed

The use of SGLT2 inhibitors was associated with similar or lower risks of fractures as incretin-based drugs, even in the high-risk patient population.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

SGLT2 Inhibitors Did Not Increase Fracture Risk in Postmenopausal Patients with T2D

Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Jeffrey B. Boord, MD, MPH
Credit: Endocrine Society

Results of the HypoPrevent study suggest the implementation of a low-cost, clinical decision support tool could reduce the risk of hypoglycemia from overtreatment in older adults with 

A quality improvement study including more than 90 adults aged 65 years and older with diabetes, results of the study indicate implementation of the study intervention, which leveraged a clinical decision support tool and shared decision-making, could cut the risk of hypoglycemia by nearly 50% and was associated with de-escalation of medications in 20% of patients.

“This study demonstrates that a low-cost clinical decision support tool, without the additional use of continuous glucose monitoring technology, can decrease the number of patients at high risk for hypoglycemia and reduce overtreatment with insulin and diabetes medications that cause hypoglycemia,” said study investigator Jeffrey B. Boord MD, MPH, of Parkview Health System and chair of the Endocrine Society’s Hypoglycemia Prevention Initiative Steering Committee.

 “The patients in our study also reported significant reductions in the negative impact of hypoglycemia on their daily lives.”

A pre-post, single-arm study conducted at a 5-site primary care practice in Pennsylvania, the HypoPrevent study was launched by Boord and colleagues to evaluate whether a 2-component intervention in primary care setting could reduce overtreatment of type 2 diabetes and hypoglycemia. For inclusion in the study, patients needed to be 65 years of age or older, treated with insulin or sulfonylureas, and have an HbA1c less than 7.0%.

Per trial protocol, participants took part in 3 clinic visits over a 6-month period. During these visits, investigators used the clinical decision support tool and shared decision-making to assess hypoglycemic risk, set individualized HbA1c goals, and adjust medication. The clinical decision support tool used in the study provided clinicians with an instructional guide for the provider-patient encounter and provided information from all study visits, including prior SDM discussions, HbA1c goals, medications, HbA1c levels, and comorbidities, so information from prior visits was accessible to clinicians at each subsequent encounter.

The primary outcomes of interest for the study were impact of use on individualized HbA1c goals and/or modifications in the use of insulin or sulfonylureas, change in the number of study patients in the at-risk group for hypoglycemia before and after the intervention, and the impact of the use on non-severe hypoglycemia events. Investigators pointed out nonsevere hypoglycemic events were assessed using the Treatment Related Impact Measure—Hypoglycemic Events (TRIM-HYPO) survey.

A total of 94 patients were enrolled in the study. This cohort had a mean age of 74 years (range, 65-93), 57% were female, and 95% were White. Additionally, 61% had a disease duration of 10 or more years, 48% had chronic kidney disease, 51% reported insulin use at baseline, and 47% reported sulfonylurea use at baseline. Of the 94 patients enrolled in study, 80 completed all 3 study visits.

Upon analysis, results indicated 20% of participants decreased or eliminated use of insulin or sulfonylurea relative to baseline use. Results also indicated an HbA1c level before and after goal setting was obtained in 53% of the study cohort. Further analysis of this patient subgroup revealed the mean HbA1c increased by a mean of 0.53% (

 <.0001) and the number of patients considered at-risk of hypoglycemia decreased by 46% (

 <.0001). Investigators noted statistically significant reductions in the impact of hypoglycemia during daily activities were observed for both the total score and each of the 5 functional domains of TRIM-HYPO.

“Because this intervention was so successful, we hope that our clinical decision support tool could be adopted for use in other primary care settings to lower the risk of hypoglycemia and improve the overall well-being of older adults with diabetes,” Boord added.

Koehn DA, Dungan KM, Wallia A, et al. Reducing hypoglycemia from overtreatment of type 2 diabetes in older adults: The HypoPrevent study [published online ahead of print, 2023 Sep 21]. 

. 2023;10.1111/jgs.18566. doi:10.1111/jgs.18566

Endocrine Society. Primary care intervention reduces hypoglycemia risk from type 2 diabetes overtreatment in older adults. Endocrine Society. September 27, 2023. Accessed September 29, 2023. https://www.endocrine.org/news-and-advocacy/news-room/2023/primary-care-intervention-reduces-hypoglycemia-risk-in-older-adults.

A new study suggests implementation of a low-cost clinical decision support tool reduces hypoglycemia risk in older adults with type 2 diabetes.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Clinical Support Tool, Shared Decision-Making Can Reduce Hypoglycemia in Older Adults

Older adults aged 65 and above who take sedative and hypnotic agents for sleep disorders or anxiety are at risk of car accidents due to impaired driving abilities.

Benzodiazepines, commonly prescribed for these conditions, can lead to sedation, impaired motor coordination, and drowsiness in older adults, affecting their ability to react to changes in the driving environment.

Medications containing noradrenaline, serotonin, histamine, acetylcholine, and GABA can also pose risks to older adults' driving abilities, causing symptoms like dizziness, drowsiness, attention deficits, cognitive difficulties, and psychomotor impairment.

SSRIs have milder side effects than older antidepressants but can still lead to sleep disturbances, agitation, dizziness, headache, and fatigue, all of which impair driving.

When adults aged ≥65 years old take sedative and hypnotic agents to treat 

, they unknowingly put themselves at risk of car accidents, according to new research. What’s more, the commonly prescribed benzodiazepines may cause sedation, impaired motor coordination, and drowsiness in older adults.

“This can impair drivers’ ability to focus and react quickly to changes in the environment, such as other vehicles, pedestrians, or traffic signals,” wrote investigators of a new study, led by David Carr, MD, of the department of medicine at Washington University.

It is not just the drug benzodiazepines either—any medicine that contains noradrenaline, serotonin, histamine, acetylcholine, and GABA.48 puts older adults at risk of car accidents.

These drugs may lead to ill effects—dizziness, drowsiness, attention deficit, cognitive difficulties, and psychomotor impairment.

Selective serotonin reuptake inhibitors (SSRIs) have milder ill effects than older antidepressants, but side effects include sleep disturbance, agitation, dizziness, headache, and fatigue—all symptoms that lead to driving impairment.

In Carr’s study, cognitively healthy older people (aged ≥65 years old) who were enrolled in the Knight Alzheimer’s Disease Research Center took the Washington University Road test. All participants had a valid driver’s license and Clinical Dementia Rating Score of 0 at baseline and subsequent visits.

Despite this score, 70 (35%) of the 198 adults received a marginal or fail rating on the road test.

Any antidepressants, serotonin, and norepinephrine reuptake inhibitors or non-steroidal anti-inflammatory drugs were associated risk of participants failing the road test, but participants who took lipid-lowering agents had a lower risk of failing.

Medicine that impairs driving also commonly causes sedation, motor coordination, hypoglycemia, blurred vision, hypotension, syncope, and ataxia. The antidepressants that cause these ill effects are benzodiazepines, sedatives and hypnotics, antihistamines, opioids, antipsychotics, and anticholinergics.

Previous systematic meta-analyses with older adult samples found that driving impairment was identified for specific medical conditions, such as dementia, Parkinson disease, and stroke. People who reported being Black also have a higher risk of driving impairment, mobility restriction, and driving cessation compared to people who reported being White.

Carr and colleagues wanted to determine whether certain classes of medication increase risk of driving impairment.

In the study, people who received a marginal/fail rating on the road test had a lower near visual acuity scores, with the mean score 63.8 at baseline (

“This cohort study found that in a cognitively healthy, community-residing sample of adults 65 years and older who were taking SSRI or SNRIs, antidepressants, sedatives or hypnotics, or NSAIDs or acetaminophen were found to have a higher risk of driving impairment on a road test (marginal/fail rating) compared to nonuse,” investigators wrote. “These results suggest that the potentially driver-impairing medication classes may increase the risk or poor driving performance over time among older drivers.”

Nonsteroidal anti-inflammatory (NSAID) drugs typically do not impact driving if taken correctly, but they can result in adverse effects, such as dizziness, lightheadedness, drowsiness, vision impairment, and difficulty concentrating.

“Long-term use of NSAIDs by older patients is common and could result in drug-drug interactions that exacerbate existing medical conditions known to contribute to driving impairment, such as hypertension and heart failure,” investigators concluded.

Carr DB, Beyene K, Doherty J, et al. Medication and Road Test Performance Among Cognitively Healthy Older Adults. 

 2023;6(9):e2335651. doi:10.1001/jamanetworkopen.2023.35651

When cognitively healthy older adults performed a road test when taking a medicine with adverse effects, 35% of participants received a marginal/fail rating.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

Older Age Does Not Cause Car Accidents—Medication with Adverse Effects Do

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Results from a prospective observational study of patients treated with washed microbiota transplantation (WMT) are highlighting its safety and efficacy for the treatment of 

Patients who underwent WMT experienced a 90.7% clinical cure rate, with no difference observed between patients with primary CDI and recurrent CDI but a slightly lower rate among those with severe and complicated CDI.

“It has been pointed out that the participants included in randomized controlled trials do not adequately represent the population of patients with CDI due to most patients who meet the guideline criteria for FMT are either ineligible or unwilling to participate in trials,” wrote investigators.

 “Therefore, we conducted this real-word study in a more representative population with diverse clinical characteristics and medical settings, aiming to better demonstrate the true efficacy and safety of WMT for CDI.”

Standard treatment for CDI involves antibiotics, but many patients continue to suffer from repeat infections. Fecal microbiota transplantation (FMT) offers a viable treatment option for patients who do not respond to antibiotic therapy and involves transferring a healthy microbiome from the feces of a donor to a recipient, which restores healthy bacteria in the lower intestine to help control CDI and keep it from coming back. WMT is a new method of FMT using washed microbiota from feces.

Senior investigator Faming Zhang, MD, PhD, vice chief of the medical center of digestive diseases at Nanjing Medical University in China, and a team of investigators assessed clinical cure rate, total abdominal symptom score, and recurrence rate in patients with CDI treated with WMT at medical centers applying for rescue WMT through the China Microbiota Transplantation System from October 1, 2021, to September 30, 2022.

To be included in the study, patients were required to have ≥ 3 liquid stools (Bristol 6-7) per day or present with confirmed intestinal obstruction and notable abdominal distention correlated with CDI, a diagnosis of CDI confirmed through laboratory tests, or colonoscopy-confirmed pseudomembranous colitis. Patients who did not receive WMT, partially responded to previous antibiotic treatment before WMT but did not meet the criteria for clinical cure, or were previously treated with FMT for episodes of CDI were excluded from analysis.

In total, investigators enrolled 54 patients with CDI who underwent a total of 105 WMTs. Among the cohort, 63% of participants were male, 68.5% were under the age of 65, and 55.6% had severe and complicated CDI. The major causes of CDI were the use of antibiotics (48.1%) and being immunocompromised (51.9%). Prior to WMT, 48.1% of patients had been treated with metronidazole/ornidazole/tinidazole, 40.7% with vancomycin, and 7.4% with other antibiotics. Of the 37 patients who experienced primary CDI, 56.7% (n = 21) underwent WMT as the first-line treatment and had not received antibiotics prior to WMT.

Upon analysis, 49 (90.7%) patients achieved clinical cure, defined by investigators as the resolution of clinical symptoms or a negative CDI test. There was no difference in the clinical cure rate between patients with primary CDI and recurrent CDI (91.89% vs 88.23%; 

= .645), as well as between patients from southern and northern China (92.31% vs 86.67%; 

= .610). Of note, the clinical cure rate among patients with severe and complicated CDI was less than those without severe and complicated CDI (83.3% vs 100.0%; 

Patients with a WHO performance score of 4 (

 = .030), a greater Charlson Comorbidity Index score (

 = .034), and a greater total abdominal symptom score (

= .010) before WMT were more likely to experience clinical failure. During the minimum 8-week follow-up period, 4 (8.16%) patients experienced CDI recurrence.

Investigators pointed out WMT-related adverse events were observed in 3.8% of the 105 WMTs, with no difference in the rate of adverse events between patients with and without severe and complicated CDI (3.33% vs 4.44%, respectively; 

= 1.00). Delivery through upper GI (5.1%) or lower GI (3.0%) did not affect the incidence of adverse events (

 = .627). Fresh (6.7%) or frozen (2.7%) microbial status also had no significant impact on the incidence of adverse events (

“The current study demonstrates the attractive efficacy and safety of WMT in patients with CDI. The broad inclusion of CDI patients with varying clinical characteristics enhances the representativeness of our real-world study, thereby providing valuable insights into clinical practice,” investigators concluded.

Wu X, Ai R, Xu J, et al. Washed microbiota transplantation for 

 infection: a national multi-center real-world study. 

Mount Sinai. Fecal Microbial Transplant. Digestive Diseases - Gastroenterology. Accessed September 28, 2023. 

https://www.mountsinai.org/care/gastroenterology/services/fecal-microbial-transplant

Johns Hopkins Medicine. Fecal Transplant. Treatments, Tests and Therapies. Accessed September 28, 2023. 

https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/fecal-transplant

More than 90% of patients with CDI treated with WMT achieved clinical cure, while only 3.8% of WMTs resulted in adverse events.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Washed Microbiota Transplantation Demonstrates Safety, Efficacy in Patients with C Diff 

Videos

An expert nurse practitioner comments on recent advances in the treatment of plaque psoriasis, as well as the continuous need for more treatment options.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Peers Perspectives

Recent Breakthroughs in Treatment of Plaque Psoriasis

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, discuss the role of advanced practice providers (APPs) within dermatology, highlighting the medical, surgical, and cosmetic categories in the space.

The Role of Advanced Practice Providers (APPs) in Dermatology

Podcasts

In this episode of MEDcast, the expert panelists examine some underutilized therapies in type 2 diabetes (T2D) and explore their potential as effective treatment choices for many patients.

Medcast Podcasts

Untapped Potentials: Exploring Overlooked Therapies for Type 2 Diabetes

A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Pharmacist-Led Interventions Can Improve HbA1c in Underserved Communities

Investigators believe their findings may help reduce the negative of self-stigma and subjective symptom reporting burdening patients with depression.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

EEG-Based Model Predicts Antidepressant Responses in Depression Patients

Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990-2019.

Immune-Mediated Inflammatory Diseases Increase Despite Available Treatment

Most patients were able to achieve clear or almost clear skin, and improvement of arthritis and difficult-to-treat areas, with guselkumab and risankizumab treatment. 

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Real-World Data Support Efficacy of IL-23 Inhibitors for Psoriatic Arthritis, Psoriasis 

This new position statement by the Congress of the European Academy of Dermatology and Venereology identified several benefits to the implementation of technological innovations in dermatologic care.


AI-Powered Smartphone Applications Seen as Promising for Dermatologic Care Use

The indication is the first for an antidepressant that selectively targets the serotonin 1A receptor—a regulator of mood and emotion.

FDA Approves Gepirone Hydrochloride Tablets for Major Depression

Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.

Of the 333 patients with PsA and 457 patients with axSpA, there were 1.09 serious infections per 100 patient years (95% CI .85 – 1.35).

Latest News

Consistent Exposure to Laundry Detergent Shown to Contribute to Emergence of Atopic Conditions

SGLT2 Inhibitors Did Not Increase Fracture Risk in Postmenopausal Patients with T2D

Clinical Support Tool, Shared Decision-Making Can Reduce Hypoglycemia in Older Adults

Older Age Does Not Cause Car Accidents—Medication with Adverse Effects Do

Washed Microbiota Transplantation Demonstrates Safety, Efficacy in Patients with C Diff